Search peptides, terms, sources/

Weight Management

Weight management research covers peptides studied for effects on appetite, food intake, energy metabolism or body weight, mostly incretin and amylin-pathway compounds tested in randomised placebo-controlled trials. Studies range from receptor assays to large multi-centre Phase 3 trials. A peptide's presence here shows its effect on weight was formally studied, not that any outcome is established.

Which peptides have been studied in weight management?

  • AOD-9604hGH Fragment 176-191

    Growth hormone fragment studied for weight management. Not licensed in the UK; its largest human trial showed no significant weight-loss benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • CagrilintideAM833

    Not licensed in the UK. Investigational long-acting amylin analogue studied for weight management, alone and with semaglutide.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • KisspeptinMetastin

    Natural reproductive hormone studied in UK trials for low sexual desire and IVF egg maturation. No UK marketing authorisation identified.

    Hormonal signallingHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • Liraglutide

    Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine
  • Mazdutide

    Not authorised in the UK; approved in China. Peptide that activates glucagon and GLP-1 receptors, studied in phase 3 trials in Chinese adults.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • RetatrutideLY3437943

    Investigational triple GIP, GLP-1 and glucagon receptor agonist studied for weight management. Not licensed in the UK; studied in a Phase 2 trial.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • Setmelanotide

    Synthetic peptide that activates the MC4 receptor, studied in rare forms of obesity. UK prescription-only medicine for three rare conditions; trials were small and do not cover common obesity.

    MelanocortinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine
  • Survodutide

    Investigational peptide that activates glucagon and GLP-1 receptors. Not authorised in the UK. Studied in phase 3 trials, all sponsor-funded.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • Tirzepatide

    Dual GIP and GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine

View in the full index

Best recorded finding for each peptide in this area

The best recorded finding for each peptide in this area. Each row grades one finding, not the peptide or the medicine.
PeptideUK statusFindingStudy typeEvidence grade
CagrilintideNot licensed in the UKStandalone Phase 2 weight trialHuman trialModerate
LiraglutideLicensed UK medicineSCALE 56-week weight trialsHuman trialLimited
MazdutideNot licensed in the UKGLORY-1, phase 3 in ChinaHuman trialStrong
RetatrutideNot licensed in the UKPhase 2 obesity trialHuman trialModerate
SemaglutideLicensed UK medicineWeight change at 68 weeksHuman trialStrong
SetmelanotideLicensed UK medicineAcquired hypothalamic obesityHuman trialModerate
SurvodutideNot licensed in the UKPhase 3 in obesity without diabetesHuman trialStrong
TirzepatideLicensed UK medicineThe SURMOUNT-1 obesity trialHuman trialStrong

"Weight Management" groups peptides that have been studied for effects on appetite, food intake, energy metabolism or body weight, most commonly incretin-mimetic and amylin-pathway compounds investigated in randomised, placebo-controlled human trials. Published research in this area spans mechanisms such as GLP-1 and GIP receptor agonism, amylin-receptor activation and lipolytic signalling, with study designs ranging from receptor-binding assays through to large multi-centre Phase 3 trials. Inclusion here reflects that a peptide's effect on weight-related endpoints has been formally investigated, not that any outcome, positive, negative or mixed, has been established as reliable.

26 sources in the library relate to this area. See them.

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.